Drugs / Patritumab deruxtecan
Trials 28 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04610528 | Dec 2020 → Jan 2022 | breast cancer | SOLTI Breast Cancer Research Group | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04676477 | Jun 2021 → Jan 2025 overdue | non-small cell lung carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03260491 | Oct 2017 → Mar 2026 overdue | non-small cell lung carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT07701941 | Aug 2026 → Jan 2031 expected | hormone receptor-positive breast cancer | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07286149 | Apr 2026 → Aug 2031 expected | lung cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06941272 | May 2025 → Dec 2030 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06686394 | Feb 2025 → Apr 2030 expected | breast cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06596694 | Nov 2024 → Dec 2028 expected | digestive system cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06469944 | Sep 2024 → Sep 2029 expected | esophageal cancer, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06445972 | Aug 2024 → May 2028 expected | esophageal cancer, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06298084 | Mar 2024 → Sep 2027 expected | HER2 positive breast carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04165070 | Dec 2019 → Feb 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02980341 | Nov 2016 → Aug 2021 | breast cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT05620914 | Jul 2025 → Apr 2026 | metastatic malignant neoplasm in the brain | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Withdrawn | No outcome recorded |
| Phase 2 | NCT06731907 | Mar 2025 → Mar 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06797635 | Mar 2025 → Dec 2029 expected | breast cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06222489 | Mar 2025 → May 2027 expected | non-small cell squamous lung carcinoma | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06383884 | Aug 2024 → Apr 2027 expected | — | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06172478 | Feb 2024 → Sep 2027 expected | breast cancer, carcinoma of esophagus, cervical cancer, endometrial cancer +7 | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 2 | NCT05865990 | Nov 2023 → Nov 2024 | breast cancer, non-small cell squamous lung carcinoma | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT05569811 | Nov 2022 → Mar 2025 overdue | breast cancer | SOLTI Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04965766 | May 2021 → Apr 2027 expected | breast cancer | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT04699630 | May 2021 → Apr 2025 | breast cancer, metastatic malignant neoplasm | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04619004 | Feb 2021 → Nov 2022 overdue | non-small cell lung carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04479436 | Sep 2020 → Feb 2022 | colorectal cancer | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07060807 | Jul 2025 → Jul 2033 expected | breast neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05338970 | Jul 2022 → May 2024 overdue | non-small cell lung carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06099639 | — | lung cancer | Daiichi Sankyo | No longer available | No outcome recorded |
Press releases naming this drug 12 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-04 | Daiichi Sankyo | HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC daiichisankyo.com ↗ |
| 2021-01-29 | Daiichi Sankyo | New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented at WCLC 2020 daiichisankyo.com ↗ |
| 2020-09-18 | Daiichi Sankyo | Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020 daiichisankyo.com ↗ |
| 2020-09-15 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer daiichisankyo.com ↗ |
| 2020-08-07 | Daiichi Sankyo | Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer daiichisankyo.com ↗ |
| 2020-07-22 | Daiichi Sankyo | Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan daiichisankyo.com ↗ |
| 2019-09-10 | Daiichi Sankyo | Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer daiichisankyo.com ↗ |
| 2019-06-03 | Daiichi Sankyo | Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting daiichisankyo.com ↗ |
| 2018-12-06 | Daiichi Sankyo | Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS) daiichisankyo.com ↗ |
| 2018-06-01 | Daiichi Sankyo | Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with HER3-Expressing Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting daiichisankyo.com ↗ |
| 2018-02-07 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer daiichisankyo.com ↗ |
| 2017-01-19 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer daiichisankyo.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Patritumab deruxtecan | “Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3...” PMID 40554742 ↗ Jun 202519“a phase 2 study evaluating efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan (HER3-DXd), in patients with HR+HER2- metastatic breast cancer” PMID 40908353 ↗ Sep 2025 |
| Known as | HER3-DXd | “Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3...” PMID 40554742 ↗ Jun 202511“This peri-operative window of opportunity study in patients with brain metastases will provide a single dose of the antibody-drug conjugate (ADC) patritumab deruxtecan...” NCT05620914 ↗ “A Phase 2 Trial of neoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan (HER3-DXd; U3-1402) With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer -...” NCT05569811 ↗ “Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate” PMID 37801674 ↗ Oct 2023 “the HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402)” PMID 33968735 ↗ Apr 2021 “patritumab deruxtecan (U3-1402; HER3-DXd) has been shown” NCT06222489 ↗ |
| Known as | MK-1022 | “Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3...” PMID 40554742 ↗ Jun 2025 |
| Known as | U3-1402 | “This peri-operative window of opportunity study in patients with brain metastases will provide a single dose of the antibody-drug conjugate (ADC) patritumab deruxtecan...” NCT05620914 ↗7“A Phase 2 Trial of neoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan (HER3-DXd; U3-1402) With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer -...” NCT05569811 ↗ “Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer” NCT04965766 ↗ “the HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402)” PMID 33968735 ↗ Apr 2021 “patritumab deruxtecan (U3-1402; HER3-DXd) has been shown” NCT06222489 ↗ “U3-1402” NCT04479436 ↗ |
| Known as | U3-1402A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594611 ↗ |
| Action | Deplete | “delivers treatment to destroy those cells” NCT06941272 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL4594611 ↗ |
| Modality | Monoclonal antibody | “a recombinant fully human anti HER3 monoclonal antibody” NCT04699630 ↗ |
| Route | Intravenous | “administered via intravenous (IV) solution” NCT02980341 ↗ |
| Target | ERBB3 | “a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab)” PMID 40554742 ↗ Jun 2025 |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL4594611 ↗ |